Cargando…
Clinicopathological Analysis and Prognostic Assessment of Transcobalamin I (TCN1) in Patients with Colorectal Tumors
BACKGROUND: Colorectal cancer (CRC) is one of the most common malignancies worldwide. Overall survival (OS) of patients is largely dependent on disease stage at diagnosis and/or surgical resection. TCN1 mainly encodes the vitamin B12 transporter, transcobalamin. Early studies show that TCN1 is a mar...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397756/ https://www.ncbi.nlm.nih.gov/pubmed/32753569 http://dx.doi.org/10.12659/MSM.923828 |
_version_ | 1783565831028867072 |
---|---|
author | Zhu, Xinqiang Yi, Kui Hou, Daorong Huang, Hailong Jiang, Xuetong Shi, Xiaohong Xing, Chungen |
author_facet | Zhu, Xinqiang Yi, Kui Hou, Daorong Huang, Hailong Jiang, Xuetong Shi, Xiaohong Xing, Chungen |
author_sort | Zhu, Xinqiang |
collection | PubMed |
description | BACKGROUND: Colorectal cancer (CRC) is one of the most common malignancies worldwide. Overall survival (OS) of patients is largely dependent on disease stage at diagnosis and/or surgical resection. TCN1 mainly encodes the vitamin B12 transporter, transcobalamin. Early studies show that TCN1 is a marker of CRC progression, but the impact of TCN1 on survival is unclear. MATERIAL/METHODS: We reviewed and analyzed colorectal tumor records, summarized the clinicopathological data, performed immunohistochemical detection of TCN1 again, and semi-quantitatively analyzed protein expression in tumor tissue, non-tumor tissue, and lymph nodes. We followed up patients for 5-year survival. RESULTS: Of 123 patients, 60 (48.7%) had a strong TCN1 immunohistochemical reaction, 36 (29.3%) had a moderate immune response, and 27 (22.0%) had weak expression. The level of immunohistochemical reactivity of TCN1 was correlated with the degree of histological differentiation (H (2.92)=4.976; P=0.083). Survival analysis showed that OS in patients with low TCN1 expression was significantly longer than that in the medium and high TCN1 expression groups (P=0.045). Five-year OS in patients with low, medium, and high TCN1 expression was 88.9%, 50.0%, and 40.0%, respectively. In univariate analysis, TCN1 immune expression was significantly correlated with the 5-year survival rate. CONCLUSIONS: Although independent risk factors affecting survival of patients with CRC are age, serum CA125, CA19-9, lymph node metastasis, and nerve invasion, negative factors affecting overall 5-year survival in TCN1 should not be ignored, because its high expression suggests a worse clinical prognosis. |
format | Online Article Text |
id | pubmed-7397756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73977562020-08-13 Clinicopathological Analysis and Prognostic Assessment of Transcobalamin I (TCN1) in Patients with Colorectal Tumors Zhu, Xinqiang Yi, Kui Hou, Daorong Huang, Hailong Jiang, Xuetong Shi, Xiaohong Xing, Chungen Med Sci Monit Clinical Research BACKGROUND: Colorectal cancer (CRC) is one of the most common malignancies worldwide. Overall survival (OS) of patients is largely dependent on disease stage at diagnosis and/or surgical resection. TCN1 mainly encodes the vitamin B12 transporter, transcobalamin. Early studies show that TCN1 is a marker of CRC progression, but the impact of TCN1 on survival is unclear. MATERIAL/METHODS: We reviewed and analyzed colorectal tumor records, summarized the clinicopathological data, performed immunohistochemical detection of TCN1 again, and semi-quantitatively analyzed protein expression in tumor tissue, non-tumor tissue, and lymph nodes. We followed up patients for 5-year survival. RESULTS: Of 123 patients, 60 (48.7%) had a strong TCN1 immunohistochemical reaction, 36 (29.3%) had a moderate immune response, and 27 (22.0%) had weak expression. The level of immunohistochemical reactivity of TCN1 was correlated with the degree of histological differentiation (H (2.92)=4.976; P=0.083). Survival analysis showed that OS in patients with low TCN1 expression was significantly longer than that in the medium and high TCN1 expression groups (P=0.045). Five-year OS in patients with low, medium, and high TCN1 expression was 88.9%, 50.0%, and 40.0%, respectively. In univariate analysis, TCN1 immune expression was significantly correlated with the 5-year survival rate. CONCLUSIONS: Although independent risk factors affecting survival of patients with CRC are age, serum CA125, CA19-9, lymph node metastasis, and nerve invasion, negative factors affecting overall 5-year survival in TCN1 should not be ignored, because its high expression suggests a worse clinical prognosis. International Scientific Literature, Inc. 2020-07-23 /pmc/articles/PMC7397756/ /pubmed/32753569 http://dx.doi.org/10.12659/MSM.923828 Text en © Med Sci Monit, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Clinical Research Zhu, Xinqiang Yi, Kui Hou, Daorong Huang, Hailong Jiang, Xuetong Shi, Xiaohong Xing, Chungen Clinicopathological Analysis and Prognostic Assessment of Transcobalamin I (TCN1) in Patients with Colorectal Tumors |
title | Clinicopathological Analysis and Prognostic Assessment of Transcobalamin I (TCN1) in Patients with Colorectal Tumors |
title_full | Clinicopathological Analysis and Prognostic Assessment of Transcobalamin I (TCN1) in Patients with Colorectal Tumors |
title_fullStr | Clinicopathological Analysis and Prognostic Assessment of Transcobalamin I (TCN1) in Patients with Colorectal Tumors |
title_full_unstemmed | Clinicopathological Analysis and Prognostic Assessment of Transcobalamin I (TCN1) in Patients with Colorectal Tumors |
title_short | Clinicopathological Analysis and Prognostic Assessment of Transcobalamin I (TCN1) in Patients with Colorectal Tumors |
title_sort | clinicopathological analysis and prognostic assessment of transcobalamin i (tcn1) in patients with colorectal tumors |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397756/ https://www.ncbi.nlm.nih.gov/pubmed/32753569 http://dx.doi.org/10.12659/MSM.923828 |
work_keys_str_mv | AT zhuxinqiang clinicopathologicalanalysisandprognosticassessmentoftranscobalaminitcn1inpatientswithcolorectaltumors AT yikui clinicopathologicalanalysisandprognosticassessmentoftranscobalaminitcn1inpatientswithcolorectaltumors AT houdaorong clinicopathologicalanalysisandprognosticassessmentoftranscobalaminitcn1inpatientswithcolorectaltumors AT huanghailong clinicopathologicalanalysisandprognosticassessmentoftranscobalaminitcn1inpatientswithcolorectaltumors AT jiangxuetong clinicopathologicalanalysisandprognosticassessmentoftranscobalaminitcn1inpatientswithcolorectaltumors AT shixiaohong clinicopathologicalanalysisandprognosticassessmentoftranscobalaminitcn1inpatientswithcolorectaltumors AT xingchungen clinicopathologicalanalysisandprognosticassessmentoftranscobalaminitcn1inpatientswithcolorectaltumors |